SINDOVIN 1mg powder for intravenous injection / infusion solution medication leaflet

L01CA02 vincristine • Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Vinca alkaloids and analogues

Vincristine is a chemotherapy medication used for the treatment of various types of cancer, including acute lymphoblastic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, and Ewing's sarcoma. It belongs to the vinca alkaloid class and works by inhibiting microtubule formation, leading to the arrest of cell division and tumor cell death.

Vincristine is administered intravenously, usually once a week, and the dosage is adjusted based on body weight and patient response. Treatment is conducted under the supervision of an oncologist, and patients are monitored for signs of toxicity.

Common side effects include peripheral neuropathy, constipation, hair loss, nausea, and fatigue. In rare cases, severe adverse reactions such as liver function impairment or bone marrow depression may occur.

Vincristine is an essential component of many chemotherapy regimens, helping to reduce tumor size and improve survival rates in cancer patients.

General data about SINDOVIN 1mg

Substance: vincristine

Date of last drug list: 01-06-2025

Commercial code: W64718001

Concentration: 1mg

Pharmaceutical form: powder for intravenous injection / infusion solution

Quantity: 1

Product type: generic

Price: 62.66 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: SINDAN PHARMA SRL - ROMANIA

Holder: TEVA B.V. - OLANDA

Number: 12494/2019/01

Shelf life: 3 years-ambalat pt comercializare: sol. reconstituita-a se utiliza imediat

Concentrations available for vincristine

1mg, 1mg/ml

Other substances similar to vincristine

Compensation lists for SINDOVIN 1mg TEVA

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

62.66 RON

62.66 RON

0.00 RON